Pfizer, Lilly Breast Cancer Drugs Slow Tumors in Studies

Experimental breast cancer drugs from Pfizer Inc. and Eli Lilly & Co. slowed or halted growth of advanced tumors in studies, potentially adding a new treatment option for patients and top-selling therapies for the companies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.